GET AHEAD OF AV FISTULA RESTENOSIS1

IN.PACT™ AV
Drug-Coated Balloon (DCB)
Watch the Video

NEW CME VIDEO MANAGING DIALYSIS ACCESS IN THE COVID-19 ENVIRONMENT

Join Dr. John Ross as he moderates a discussion about:

  • Incorporating new COVID-19 guidelines
  • The role of technology
  • Updated KDOQI guidelines

WATCH VIDEO

56% FEWER REINTERVENTIONS1 MORE OF WHAT MATTERS

The IN.PACT AV DCB has been demonstrated superior to PTA in increasing patency and reducing reinterventions.1

View Product Details

IN.PACT AV DCB HIGHEST REPORTED PRIMARY PATENCY

In an AV DCB study1    

78% Highest Reported Access Circuit Primary Patency*1

86% Highest Reported Target Lesion Primary Patency*1

Fewer is Better

By enabling dramatically fewer AV fistula interventions,1 the IN.PACT AV DCB can make a real impact ― clinically, financially,2 and emotionally.

Hear from Dominick ―
a patient story.

COME SEE US

Visit us at upcoming events and learn about other products in the Medtronic Peripheral portfolio.

Conference Information

CONTACT US

Request more information about IN.PACT AV or any other product in our Peripheral portfolio.

SUBMIT A REQUEST
*

In an AV DCB study.

References

1

Results from the IN.PACT™ AV Access Clinical Trial found in the IN.PACT™ AV drug-coated balloon (DCB) Instructions for Use (IFU).

2

Thamer M, Lee TC, Wasse H, et al. Medicare Costs Associated With Arteriovenous Fistulas Among US Hemodialysis Patients. Am J Kidney Dis. July 1, 2018;72(1):10-18.

Target Lesion Primary Patency Rate based on KM estimates: Defined as freedom from clinically driven target lesion revascularization (CD-TLR) or access circuit thrombosis calculated at 180 days.

Access Circuit Primary Patency based on KM estimates: Defined as freedom from reintervention in the access circuit or access circuit thrombosis calculated at 180 days.

Reduction in reinterventions: Defined as the number of interventions required to maintain target lesion primary patency calculated at 210 days.